EXELIXIS_XL092-303

RECRUITMENT COMPLETED 

Research code: EXELIXIS_XL092-303
Research name: Randomised, open-label, phase III research evaluating the use of XL092 in combination with atezolizumab versus regorafenib in patients with metastatic colorectal cancer
Indication: colorectal cancer
Principal researcher: Ewa Chmielowska, MD, PhD
Research population: patients with metastatic colorectal cancer after treatment with oxalipaltin and irinotecan and not treated with lonsurf - i.e. after the second and before the third line of treatment.
Investigated drug: XL092 with atezolizumab